Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND study

Matti Aapro, Joanna Van Erps, Karen MacDonald, Pierre Soubeyran, Michael Muenzberg, Matthew Turner, Hans Warrinnier, Tara Albrecht, Ivo L Abraham

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: To model the relationship between scores for practicing in congruence (CSs; 0-10) with EORTC guidelines for erythropoietic proteins (EPs) and haemoglobin (Hb) outcomes observed in the validation study of the RESPOND system. Methods: Thirty four patient pairs matched on cancer type and chemotherapy in pre- (retrospective; clinicians not using RESPOND) and post-cohorts (prospective; clinicians using RESPOND) followed over 4 months following EP treatment initiation. CSs quantify the extent that care was guideline-adherent. Linear and logistic regressions controlling for cohort examined Hb outcomes as a function of CSs. Results: A one-point increase in CS was associated with 0.60 g/dL increase in Hb at month 4 (R2 = 0.40) and 0.56 g/dL increase in Hb change from month 1-4 (R2 = 0.33). Each one-point increase in CS increased the odds of reaching Hb ≥ 11 g/dL by 3.14 (R2 = 0.42) and Hb ≥ 12 g/dL by 2.77 (R2 = 0.45). Conclusion: Guideline-adherent EP treatment may improve Hb outcomes but specifically designed outcomes studies are necessary.

Original languageEnglish (US)
Pages (from-to)8-11
Number of pages4
JournalEuropean Journal of Cancer
Volume45
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Anemia
Hemoglobins
Guidelines
Neoplasms
Proteins
Validation Studies
Linear Models
Logistic Models
Outcome Assessment (Health Care)
Drug Therapy
Therapeutics

Keywords

  • Anaemia
  • Erythropoietin
  • Evidence-based practice guidelines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome : Initial evidence from the RESPOND study. / Aapro, Matti; Van Erps, Joanna; MacDonald, Karen; Soubeyran, Pierre; Muenzberg, Michael; Turner, Matthew; Warrinnier, Hans; Albrecht, Tara; Abraham, Ivo L.

In: European Journal of Cancer, Vol. 45, No. 1, 01.2009, p. 8-11.

Research output: Contribution to journalArticle

Aapro, Matti ; Van Erps, Joanna ; MacDonald, Karen ; Soubeyran, Pierre ; Muenzberg, Michael ; Turner, Matthew ; Warrinnier, Hans ; Albrecht, Tara ; Abraham, Ivo L. / Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome : Initial evidence from the RESPOND study. In: European Journal of Cancer. 2009 ; Vol. 45, No. 1. pp. 8-11.
@article{0b4f1565ffc64fafbb8ccf8756d63256,
title = "Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND study",
abstract = "Purpose: To model the relationship between scores for practicing in congruence (CSs; 0-10) with EORTC guidelines for erythropoietic proteins (EPs) and haemoglobin (Hb) outcomes observed in the validation study of the RESPOND system. Methods: Thirty four patient pairs matched on cancer type and chemotherapy in pre- (retrospective; clinicians not using RESPOND) and post-cohorts (prospective; clinicians using RESPOND) followed over 4 months following EP treatment initiation. CSs quantify the extent that care was guideline-adherent. Linear and logistic regressions controlling for cohort examined Hb outcomes as a function of CSs. Results: A one-point increase in CS was associated with 0.60 g/dL increase in Hb at month 4 (R2 = 0.40) and 0.56 g/dL increase in Hb change from month 1-4 (R2 = 0.33). Each one-point increase in CS increased the odds of reaching Hb ≥ 11 g/dL by 3.14 (R2 = 0.42) and Hb ≥ 12 g/dL by 2.77 (R2 = 0.45). Conclusion: Guideline-adherent EP treatment may improve Hb outcomes but specifically designed outcomes studies are necessary.",
keywords = "Anaemia, Erythropoietin, Evidence-based practice guidelines",
author = "Matti Aapro and {Van Erps}, Joanna and Karen MacDonald and Pierre Soubeyran and Michael Muenzberg and Matthew Turner and Hans Warrinnier and Tara Albrecht and Abraham, {Ivo L}",
year = "2009",
month = "1",
doi = "10.1016/j.ejca.2008.09.036",
language = "English (US)",
volume = "45",
pages = "8--11",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome

T2 - Initial evidence from the RESPOND study

AU - Aapro, Matti

AU - Van Erps, Joanna

AU - MacDonald, Karen

AU - Soubeyran, Pierre

AU - Muenzberg, Michael

AU - Turner, Matthew

AU - Warrinnier, Hans

AU - Albrecht, Tara

AU - Abraham, Ivo L

PY - 2009/1

Y1 - 2009/1

N2 - Purpose: To model the relationship between scores for practicing in congruence (CSs; 0-10) with EORTC guidelines for erythropoietic proteins (EPs) and haemoglobin (Hb) outcomes observed in the validation study of the RESPOND system. Methods: Thirty four patient pairs matched on cancer type and chemotherapy in pre- (retrospective; clinicians not using RESPOND) and post-cohorts (prospective; clinicians using RESPOND) followed over 4 months following EP treatment initiation. CSs quantify the extent that care was guideline-adherent. Linear and logistic regressions controlling for cohort examined Hb outcomes as a function of CSs. Results: A one-point increase in CS was associated with 0.60 g/dL increase in Hb at month 4 (R2 = 0.40) and 0.56 g/dL increase in Hb change from month 1-4 (R2 = 0.33). Each one-point increase in CS increased the odds of reaching Hb ≥ 11 g/dL by 3.14 (R2 = 0.42) and Hb ≥ 12 g/dL by 2.77 (R2 = 0.45). Conclusion: Guideline-adherent EP treatment may improve Hb outcomes but specifically designed outcomes studies are necessary.

AB - Purpose: To model the relationship between scores for practicing in congruence (CSs; 0-10) with EORTC guidelines for erythropoietic proteins (EPs) and haemoglobin (Hb) outcomes observed in the validation study of the RESPOND system. Methods: Thirty four patient pairs matched on cancer type and chemotherapy in pre- (retrospective; clinicians not using RESPOND) and post-cohorts (prospective; clinicians using RESPOND) followed over 4 months following EP treatment initiation. CSs quantify the extent that care was guideline-adherent. Linear and logistic regressions controlling for cohort examined Hb outcomes as a function of CSs. Results: A one-point increase in CS was associated with 0.60 g/dL increase in Hb at month 4 (R2 = 0.40) and 0.56 g/dL increase in Hb change from month 1-4 (R2 = 0.33). Each one-point increase in CS increased the odds of reaching Hb ≥ 11 g/dL by 3.14 (R2 = 0.42) and Hb ≥ 12 g/dL by 2.77 (R2 = 0.45). Conclusion: Guideline-adherent EP treatment may improve Hb outcomes but specifically designed outcomes studies are necessary.

KW - Anaemia

KW - Erythropoietin

KW - Evidence-based practice guidelines

UR - http://www.scopus.com/inward/record.url?scp=57749201142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57749201142&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2008.09.036

DO - 10.1016/j.ejca.2008.09.036

M3 - Article

C2 - 19058959

AN - SCOPUS:57749201142

VL - 45

SP - 8

EP - 11

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 1

ER -